+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin



Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin



Clinical and Applied Thrombosis/Hemostasis 2018: 1076029618798944



Due to variable pharmacokinetic properties, therapeutic anticoagulation with continuous unfractionated heparin (UFH) requires ongoing laboratory monitoring, generally with activated partial thromboplastin time (aPTT). In the ambulatory setting, clinicians who manage warfarin therapy often use time in the therapeutic range (TTR) to estimate a percentage of time the international normalized ratio is therapeutic. We applied the TTR concept to aPTT monitoring for therapeutic UFH and used 2 methodologies for estimation: percentage of aPTT values in range (%aIR) and a modification of the Rosendaal method (mod-Rosendaal). This study included adult inpatients admitted between September 30, 2015, and September 30, 2016, at Brigham and Women's Hospital. For each patient, all available aPTT values were extracted to calculate 2 individual TTRs according to each methodology. Comparison between methods was performed using Student t test, and correlation was assessed with simple linear regression. A total of 255 patients were included in this study. The major outcome of TTR estimation was significantly higher using mod-Rosendaal (43.7% [26.5%]) versus %aIR (37.7% [25.7%], P = .012) by a mean difference of 6% points (95% confidence interval: 1.3-10.7). Time in the therapeutic range estimated by mod-Rosendaal significantly correlated with those estimated by %aIR ( r = 0.84, P < .001). Further studies should evaluate the correlation between TTR and clinical outcomes and establish a benchmark for quality therapeutic anticoagulation with continuous UFH.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065954315

Download citation: RISBibTeXText

PMID: 30213200

DOI: 10.1177/1076029618798944


Related references

Activated clotting time post therapeutic anticoagulation with unfractionated heparin in patients undergoing elective percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi 43(5): 408-412, 2015

Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin. Thrombosis Research 175: 53-58, 2019

Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Canadian Journal of Cardiology 32(10): 1247.E23-1247.E28, 2016

Comparison of Time to Therapeutic aPTT in Patients Who Received Continuous Unfractionated Heparin After Implementation of Pharmacy-wide Intervention Alerts. Hospital Pharmacy 51(8): 656-661, 2016

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children. Journal of Thrombosis and Haemostasis 9(5): 1090-1092, 2011

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2331-2332, 2012

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2332-2333, 2012

Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Archives of Internal Medicine 161(3): 385-391, 2001

Safety and efficacy of the use of institutional unfractionated heparin protocols for therapeutic anticoagulation in obese patients: a retrospective chart review. Blood Coagulation and Fibrinolysis 26(6): 655-660, 2015

Establishing a new therapeutic activated partial thromboplastin time range for unfractionated heparin for acute coronary syndromes. Journal of the American College of Cardiology 43(5 Suppl. A): 289A, 2004

Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. American Journal of Cardiology 93(2): 247-250, 2004

Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin. Frontiers in Pharmacology 9: 1052, 2018

Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration. Critical Care Medicine 26(7): 1208-1212, 1998

Initiation of anticoagulation after cardiac surgery A prospective cohort study of efficacy, safety, and cost with low molecular weight heparin bridging in lieu of continuous intravenous unfractionated heparin. Journal of the American College of Cardiology 39(5 Suppl. A): 428A, 2002

Lack of correlation between aPTT, anti-Xa activity, and heparin dose in children receiving therapeutic doses of unfractionated heparin. Pediatric Research 53(4 Part 2): 284A, 2003